2-苯基四氢-2H-吡喃-4-醇 | 82065-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 2-苯基四氢-2H-吡喃-4-醇
• 英文名称: cis-2-phenyl-tetrahydro-2H-pyran-4-ol
• 英文别名: 2-Phenyltetrahydro-2H-pyran-4-OL；2-phenyloxan-4-ol
• CAS: 82065-19-8
• 化学式: C₁₁H₁₄O₂
• mdl: MFCD12025409
• 分子量: 178.231
• InChiKey: VPXLNWRTGPPGRS-UHFFFAOYSA-N

物化性质

• 沸点：
  329.3±42.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  2-苯基四氢-2H-吡喃-4-醇 在 sodium methylate 、 四丁基碘化铵 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Identification of a novel and orally available benzimidazole derivative as an NPY Y5 receptor antagonist with in vivo efficacy

  摘要：

  Optimization of lead compound 2 is described, mainly focusing on modification at the C-2 position of the benzimidazole core. Replacement of the phenyl linker of 2 with saturated rings resulted in identification of compound 8b which combines high Y5 receptor binding affinity with a good ADME profile leading to in vivo efficacy. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.025
• 作为产物：
  描述：

  1-phenyl-5-tributylstannylpentane-1,3-diol 在 lead(IV) acetate 作用下， 以 苯 为溶剂， 反应 2.0h， 以82%的产率得到2-苯基四氢-2H-吡喃-4-醇
  参考文献：
  名称：

  5-锡烷基-1,3-戊二醇衍生物与四乙酸铅的分子内氧化环化

  摘要：

  5-锡烷基-1，3-戊二醇衍生物的氧化环化以优异的产率得到相应的4-羟基四氢吡喃，并且还描述了其在合成二氧杂双环癸烷12和4-羟基-δ-内酯14中的应用。

  DOI：

  10.1039/c39900001492

文献信息

• [EN] 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZOLO[4,3-A]PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2012062750A1

  公开（公告）日：2012-05-18

  The present invention relates to novel triazolo [4,3-a]pyridine derivatives of Formula (I), wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及式(I)的新三唑[4,3-a]吡啶衍生物，其中所有基团均如权利要求中所定义。根据发明的化合物是代谢型谷氨酸受体2型("mGluR2")的正变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及mGluR2亚型的代谢型受体的疾病。本发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病。
• Investigation of Prins reaction for the synthesis of 2, 4- disubstituted tetrahydropyran derivatives and 1, 3-dioxanes using polyaniline supported acid as reusable catalyst
  作者：KALYAN JYOTI BORAH、RULI BORAH

  DOI：10.1007/s12039-011-0122-3

  日期：2011.9

  were investigated for the synthesis of 1, 3-dioxane in dichloromethane under reflux and at ambient temperature. The Prins cyclization of 3-butene-1-ol with aromatic aldehydes yielded 2,4- disubstituted tetrahydropyran ether 4 as single product in dichloromethane using both PANI-TsOH and PANI-FeCL3 as reusable acid catalysts. Both catalysts were investigated for the synthesis of 1, 3-dioxane in dichloromethane

  使用聚苯胺负载的TsOH（PANI-TsOH）和FeCl 3（PANI- FeCl 3）作为可重复使用的酸催化剂并形成2,4-二取代的二甲苯，在二氯甲烷中回流条件下，观察到高烯丙基醇与多种醛类的Prins环化反应。四氢吡喃醚为单一产物。在4-，3-和2-硝基苯甲醛的情况下，反应生成醛和均烯丙基醇的缩醛作为单一产物。另外，研究了两种催化剂在回流和环境温度下在二氯甲烷中合成1，3-二恶烷的方法。 使用PANI-TsOH和PANI-FeCL 3作为可重复使用的酸催化剂，将3-丁烯-1-醇与芳族醛进行Prins环化，生成2,4-二取代的四氢吡喃醚4，为二氯甲烷中的单一产物。研究了两种催化剂在二氯甲烷中合成1，3-二恶烷的方法。
• [EN] NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS<br/>[FR] NOUVELLES PIPÉRIDINYL-1,3-DIHYDROBENZOIMIDAZOL-2-ONES COMME AGONISTES DE M1
  申请人：LUNDBECK & CO AS H

  公开号：WO2009124882A1

  公开（公告）日：2009-10-15

  The present invention relates to novel M1 agonistic compounds of the present invention and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.

  本发明涉及本发明的新型M1激动剂化合物及其在治疗与精神分裂症相关的认知障碍以及在治疗由肌动蛋白M1受体介导的其他疾病中的应用。
• Enzymatic kinetic resolution of racemic 4-tetrahydropyranols by Candida rugosa lipase
  作者：J.S. Yadav、B.V.Subba Reddy、B. Padmavani、Ch. Venugopal、A.Bhaskar Rao

  DOI：10.1016/j.tetlet.2007.04.091

  日期：2007.6

  Enzymatic kinetic resolution of (±)-hydroxytetrahydropyrans has been achieved for the first time by means of lipase-mediated transesterification to afford optically active (2S,4R)-tetrahydropyranyl acetates and (2R,4S)-tetrahydropyranols in excellent yields with high enantioselectivity. Absolute configurations of the tetrahydropyranyl acetates were assigned as (S) by chemical correlation.

  （±）-羟基四氢吡喃的酶促动力学拆分首次通过脂肪酶介导的酯交换反应实现，从而以优异的产率提供了光学活性的（2 S，4 R）-四氢吡喃乙酸酯和（2 R，4 S）-四氢吡喃酚具有高对映选择性。通过化学相关性将乙酸四氢吡喃酯的绝对构型指定为（S）。
• Purine and imidazopyridine derivatives for immunosuppression
  申请人：Ohlmeyer J. Michael

  公开号：US20070021443A1

  公开（公告）日：2007-01-25

  The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas:

  本发明提供了新型嘌呤和咪唑吡啶衍生物，可用于预防和治疗自身免疫性疾病、炎症性疾病、肥大细胞介导疾病和移植排斥。这些化合物的一般式如下：